Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug interaction studies: study design, data analysis, and implications for dosing and labeling.

S-M Huang1, R Temple, D C Throckmorton

  • 1Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. shiewmei.Huang@Fda.hhs.gov

Clinical Pharmacology and Therapeutics
|January 30, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRNDE impacts the proliferation of osteoclast by estrogen deficiency in postmenopausal osteoporosis.

European review for medical and pharmacological sciences·2018
Same author

Effect of combined epidural anaesthesia on tumor-infiltrating lymphocytes in lung adenocarcinoma: a prospective exploratory sub-analysis.

Acta anaesthesiologica Scandinavica·2018
Same author

PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.

Clinical pharmacology and therapeutics·2017
Same author

Risk-benefit perception of pregnancy among breast cancer survivors.

European journal of cancer care·2017
Same author

Cancer Therapy: Shooting for the Moon.

Clinical pharmacology and therapeutics·2017
Same author

Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association.

Oncogene·2017

Regulatory agencies like the Food and Drug Administration (FDA) issue guidances to direct drug development. These guidelines ensure public participation and cover key areas like drug interactions and patient data.

Area of Science:

  • Pharmacology
  • Drug Development
  • Regulatory Science

Background:

  • Regulatory agencies communicate essential information to drug sponsors through guidances.
  • The Food and Drug Administration (FDA) in the US and the International Council for Harmonisation (ICH) issue domestic and international guidances, respectively.
  • Over 400 FDA guidances are available, developed through Good Guidance Practices to ensure public input.

Purpose of the Study:

  • To highlight the role of regulatory guidances in drug development.
  • To underscore the importance of public participation in developing these guidances.
  • To identify key clinical pharmacology areas addressed by recent FDA guidances.

Main Methods:

  • Review of FDA guidance documents and regulatory processes.

Related Experiment Videos

  • Analysis of the content and scope of clinical pharmacology guidances.
  • Examination of the Good Guidance Practices framework.

    • Main Results:

    • Guidances are a primary tool for regulatory communication and drug development direction.
    • The FDA has issued numerous guidances, with over 400 available.
    • Recent clinical pharmacology guidances focus on critical areas such as renal/hepatic impairment pharmacokinetics, dose-response, and drug-drug interactions.

    Conclusions:

    • Regulatory guidances are crucial for effective drug development and sponsor communication.
    • The Good Guidance Practices process ensures transparency and public involvement.
    • Clinical pharmacology guidances provide essential direction for key aspects of drug research and development.